Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery

Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.

PART A Synthesis and characterization of PLGA nanoparticles for drug delivery 1. History, introduction, and properties of PLGA nanoparticles as drug delivery carriers 2. Preparation and characterization of PLGA nanoparticles 3. Drug loading methods and mechanism of drug release from PLGA nanoparticles 4. Biofate and cellular interactions of PLGA nanoparticles

PART B Application of PLGA nanoparticles in drug delivery 5. Targeting strategies using PLGA nanoparticles for efficient drug delivery 6. Current progress in PLGA-based nanoparticles for treatment of cancer diseases 7. PLGA-based nanoparticles for enhanced diagnosis and cancer therapy 8. PLGA-based nanoparticles for the treatment of inflammatory diseases 9. PLGA-based nanoparticles for treatment of cerebral diseases 10. PLGA-based nanoparticles for treatment of cardiovascular diseases 11. PLGA-based nanoparticles for treatment of infectious diseases 12. PLGA-based nanoparticles as regenerative medicine 13. Photodynamic and photothermal therapy using PLGA nanoparticles 14. Gene therapy using PLGA nanoparticles

PART C Recent advances and regulatory aspects in PLGA nanoparticles 15. Hybrid PLGA nanoparticles as advanced drug delivery and theranostic applications 16. Clinical translation of PLGA nanoparticles into the market 17. Biological toxicity and environmental hazards associated with PLGA nanoparticles 18. PLGA nanoparticles: Current uses and emerging trends